Nothing said here yet.
to join the conversation.
| Brennan David RDirector | Sell | 25,000 | $3.1M | Wed, Sep 9 |
| SHAROKY MELVIN MDDirector | Sell | 5,000 | $637.6K | Mon, Aug 17 |
| Josh Gottheimer | Sell | $8.0K | Wed, Jun 10 | Tue, Jul 7 |
Insmed (INSM) just combined a fresh earnings update with higher 2026 revenue guidance for its key therapies, giving investors new numbers to weigh against a still loss-making but evolving biopharma business.
Insmed (NasdaqGS: INSM) reported the commercial launch of BRINSUPRI tablets in Japan for non cystic fibrosis bronchiectasis. BRINSUPRI is described as the first approved therapy in Japan for patients with non cystic fibrosis bronchiectasis.
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
For questions about this article or underlying research, email [email protected].
Key TakeawaysInsmed shares jumped 12% after third-quarter revenue of $524. 4 million beat expectations, led by $400.
Insmed (NASDAQ:INSM) reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insmed (INSM) delivered earnings and revenue surprises of -35.29% and +4.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
(INSM) on Thursday reported a loss of $100.The Bridgewater, New Jersey-based company said it had a loss of 46 cents per share.